Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine

Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to initiate in second half of 2019 Agreement expands Alexion’s amyloidosis portfolio Eidos to receive upfront payment of $25 million and equity investment […]

BridgeBio Pharma’s Origin Biosciences Presents New Data on the Natural History of Molybdenum Cofactor Deficiency (MoCD) Type A at the Society of the Study of Inborn Errors of Metabolism (SSIEM) Conference

This landmark study is a comprehensive global survey of the natural history of MoCD Type A Results continue to suggest urgent need for new therapies in MoCD Type A, with median survival of <4 years and rapid disease onset within the first month of life for most patients Continue to anticipate initiating a rolling New […]

BridgeBio Pharma expands its research into neuromuscular disease to include Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) with new subsidiary ML Bio Solutions

Provides BridgeBio with leading scientific expertise to develop oral small molecule therapy for LGMD2i CHARLOTTE, NC and SAN FRANCISCO, CA – September 5, 2019 – BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced ML Bio Solutions as a new subsidiary dedicated to developing BBP-418, a substrate supplementation therapy for the treatment of Limb-Girdle Muscular Dystrophy Type […]